Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
ASCO Cancer Clinical Trials

ASCO 2024 Wrap-Up Podcast

  • Analysis

Executive Summary

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting. 

After the dust settled on the recent American Society of Clinical Oncology (ASCO) annual meeting, held 31 May-4 June in Chicago, Scrip's Alaric DeArment joined the Datamonitor Healthcare podcast to discuss top highlights from the meeting. 

Topics discussed include neoadjuvant treatment of melanoma, non-muscle invasive bladder cancer, multiple myeloma and non-small cell lung cancer – as well as updates on Merus's closely watched MCLA-145, community use of CAR-T and drug shortages. 

Table

View full table

Topics

Tags:
ASCO Cancer Clinical Trials
Latest Headlines

Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s

Cartesian Looks To Chart The Way For CAR-T In Autoimmune Disease

Amid Growing Pandemic Fears, Moderna Gets BARDA Funding For Flu Program

Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics

See All
UsernamePublicRestriction

Register

SC150453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By